tbuckley/cabot-search huggingface dataset:
PTU-052 Impact of body mass index on the outcome of liver transplantation in children
Authors: A Hakeem, G Marangoni, S Chapman, R Young, A Nair, M Attia, P McClean, K R Prasad
Journal: Gut (2012)

<h3>Introduction</h3> The impact of poor nutritional status on the outcome following liver transplantation in children is well recognised. Recently studies in adults and children have reported variable effects of obesity on post transplant morbidity and mortality. This study examines the impact of pretransplant body mass index (BMI) on the outcome of liver transplantation in the current era in consecutive children from a single centre. <h3>Methods</h3> Data were retrieved from a prospectively maintained institutional database from 1994 to 2009. Patients were stratified into five BMI categories established by the WHO according to their Z scores: severe thinness (−3), thinness (-2), normal weight (0), overweight (+2) and obese (+3). Primary outcome was to evaluate post-operative morbidity and secondary measures were overall patient and graft survival. Categorical variables were analysed by <i>χ<sup>2</sup></i>, and continuous variables by one-way ANOVA. Kaplan–Meier curves were used to study patient and graft survival. <h3>Results</h3> 146 paediatric liver transplants recipients were identified, of which 132 patients with height and weight data were included. 12.2% of patients were underweight (Z score −2 and −3), 8.3% were overweight (Z score +2 and +3) and the remaining 79.5% were normal weight for age. The overall morbidity was higher in underweight recipients in comparison to normal weight (81.2% vs 42.8%, p=0.006). Post-operative septic events were common in underweight recipients in comparison to normal weight recipients (75.0% vs 25.7%, p&lt;0.001). Underweight patients had significantly longer intensive care stay than normal weight patients (mean 5.6 vs 3.1 days, p=0.029). The length of ventilation period was longer in underweight recipients in comparison to normal weight recipients (mean 3.4 vs 0.9 days, p=0.001). There was no difference in the overall length of post-operative hospital stay between underweight and normal weight recipients (mean 34.2 vs 30.9 days, p=0.602). There was no difference in the post-operative septic events, ITU stay, ventilatory period and hospital stay between overweight and normal weight. There was no difference in overall graft (p=0.949) and patient survival (p=0.984) between the three groups. <h3>Conclusion</h3> This is the only reported UK series on BMI and outcome following paediatric liver transplantation. Despite current standards of peritransplant management we have demonstrated increased overall morbidity in underweight patients, with increased rates of post-operative septic complications, longer ventilatory period, and increased length of intensive care stay. However, unlike earlier studies, patient and graft survival were not affected. This study does not demonstrate any effect of obesity on post transplant morbidity or mortality. <h3>Competing interests</h3> None declared.
Recombinant Molecules May Mean Improved Toxin Therapies
Authors: J. Bowersox
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Recombinant Molecules May Mean Improved Toxin Therapies Get access John Bowersox John Bowersox Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 19, 7 October 1992, Pages 1466–1468, https://doi.org/10.1093/jnci/84.19.1466 Published: 07 October 1992
Abstract 3714: Metabolomics and proteomics reveal inhibition of glycolysis in withaferin A-mediated prevention of mammary carcinogenesis in MMTV-neu mice.
Authors: Shivendra V. Singh, Eun-Ryeong Hahm, Joomin Lee, Su-Hyeong Kim, Anuradha Sehrawat, Julie A. Arlotti
Journal: Cancer Research (2013)

Abstract Plants used in Ayurvedic medicine, which has been practiced for centuries in India for the treatment of different ailments, continue to draw attention for identification of novel small molecule cancer chemopreventive agents. Withaferin A (WA) is one such promising small molecule constituent of the medicinal plant Withania somnifera (also known as Ashwagandha) with in vivo activity against xenografted human breast cancer cells. We have also shown recently that mammary cancer development and pulmonary metastasis in MMTV-neu transgenic mice is inhibited significantly by WA administration. In the present study, we performed metabolomics profiling using plasma and tumor tissues (n=8) and proteomics profiling using tumor tissues (n=3) from control and WA-treated MMTV-neu mice to gain insights into the mechanism underlying in vivo preventive effect of WA. A total of 320 and 328 biochemicals of known identity were detectable in the plasma and tumor tissue, respectively. The WA-mediated mammary cancer prevention in MMTV-neu mice was associated with a statistically significant alteration (P≤0.05) in the levels of 76 biochemicals in the plasma (24 increase, 52 decrease). Metabolomics using tumor tissues revealed alterations in the levels of 24 biochemicals (2 increase, 24 decrease) upon WA administration. One change that was highly consistent in the plasma and tumor tissue from WA-treated mice compared to controls was a decrease in glucose utilization, glycolysis, and TCA cycle activity. Proteomics using tumor tissues confirmed downregulation of many glycolysis-related proteins in the tumor of WA-treated mice compared with control, including M2-type pyruvate kinase, phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, and fructose-bisphosphate aldolase A isoform 2. Downregulation of TCA cycle-related proteins in the tumor of WA-treated mice compared with control included pyruvate carboxylase and isocitrate dehydrogenase. Other altered biochemicals were reflective of changes in arginine metabolism, polyamine biosynthesis, glutathione metabolism, lipid metabolism, and catabolism of branched-chain amino acids. These observations indicate that WA treatment prevents mammary cancer in MMTV-neu mice by suppressing glycolysis (Warburg effect) and TCA cycle. This study was supported by the grant CA142604 awarded by the National Cancer Institute. Citation Format: Shivendra V. Singh, Eun-Ryeong Hahm, Joomin Lee, Su-Hyeong Kim, Anuradha Sehrawat, Julie A. Arlotti. Metabolomics and proteomics reveal inhibition of glycolysis in withaferin A-mediated prevention of mammary carcinogenesis in MMTV-neu mice. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3714. doi:10.1158/1538-7445.AM2013-3714
AB0509 Deep Vein Thrombosis in Patients with Antiphospholipidic Syndrome and Lupus: the Role of Systemic Inflammation
Authors: S. Caraiola, C. Jurcut, D. Nitescu, A. Nicolau, R. Jurcut, A. Baicus, C. Baicus, C. Tanasescu
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Antiphospholipid syndrome (APLS) is classically associated venous or arterial thrombotic events. However, the predictors for occurrence of deep vein thrombosis in patients with APLS and systemic lupus erythematosus (SLE) are incompletely evaluated. <h3>Objectives</h3> The aim of this study was to evaluate the impact of systemic inflammation in patients with APLS secondary to SLE. <h3>Methods</h3> In 47 patients with APLS secondary to SLE, we performed the evaluation of traditional risk factors associated with DVT. We assessed the inflammation parameters [erythrocyte sedimentation rate (ESR), fibrinogen and C-reactive protein (CRP) levels]. We divided the study group in two subgroups: A- patients with DVT; and B- patients without DVT or any other thrombotic event. <h3>Results</h3> In our study group 18 (38.3%) patients were diagnosed with DVT. Mean age, sex distribution, smoking rate, obesity parameters (body mass index, abdominal circumference, wais-to-hip ratio) were similar in both subgroups. ESR (29.76±4.71 vs 19.71±2.63, p=0.05), fibrinogen (375.88±18.26 vs 326.71±12.45, p=0.02), CRP (12.09±3.68 vs 3.35±0.70, p=0.006) were found to have higher values in patients with DVT. However, in multivariate analysis, only CRP was independently associated with DVT (p=0.03). <h3>Conclusions</h3> Inflammation seems to be one of the pathogenic pathways in patients with APLS secondary to SLE and DVT. Further studies are required in order to have valid conclusions. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5743
AB0229 Fatigue in Rheumatoid Arthritis Patients with Low Disease-Activity
Authors: C. Bode, L. Lenferink, S. Nikolaus, H. Vonkeman
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Unless effective pharmacological treatment for controlling disease-activity in rheumatoid arthritis, the majority of patients report clinically relevant fatigue which challenges the view of disease-activity as main cause of elevated levels of fatigue. <h3>Objectives</h3> The primary aim of this study was to analyse the prevalence of fatigue in RA patients with very low disease-activity, by using a novel multidimensional fatigue questionnaire (BRAF-MDQ). As the Dutch version was not yet validated, the second aim was to psychometrically evaluate the Dutch BRAF-MDQ. <h3>Methods</h3> Data of 199 RA patients (69% women, mean age 59 years, mean DAS-28 =1.99) were selected from a multi-centre randomized clinical trial. Firstly, the prevalence rates of clinical important levels of fatigue were examined and Spearman Rho correlations were used to determine how fatigue was related to disease-activity. Secondly, the dimensional structure, internal consistency, discriminant validity, distinctiveness, reliability, construct validity and possible floor- and ceiling effects were examined to psychometrically evaluate the BRAF-MDQ. <h3>Results</h3> Clinically relevant fatigue was present in 73% of the patients. The correlation coefficients between disease-activity and dimensions of fatigue ranged from 0.05 to 0.09. The dimensional structure of the BRAF-MDQ was broadly confirmed, but major floor effects were detected. <h3>Conclusions</h3> The findings indicate that even though RA inflammation is clinically under control, the majority of the patients still reported clinically relevant fatigue. Not all items of BRAF-MDQ are equally suitable for patients with low disease-activity, pointing to possibilities for improving fatigue measurement by, for example, adaptive testing methodologies. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4619
Abstract LB-435: Treatment decision-making for clinically localized Gleason score 6 prostate cancer: What younger men choose and why
Authors: Abhinav Sidana, Bruce Trock, Zhaoyong Feng, David Hernandez, Jonathan Epstein
Journal: Cancer Research (2010)

Abstract Introduction: This study identifies various treatment related information sources used by young men with prostate cancer (&amp;lt;50 years) and evaluates the association between decision making preferences and sociodemographic factors. Methods: A survey was sent to 986 men under 50 years of age diagnosed with Gleason 6 prostate cancer from the consult service of one of the authors at Johns Hopkins Department of Pathology between 2001 and 2005. Results: 488 completed questionnaires were received. Physicians and internet were two most common information sources used by the patients. Physicians were a more important information source for white men (p=0.04) and those with higher education (p=0.036). Family was an important information source in married men (p&amp;lt;0.001) and those with higher education (p&amp;lt;0.001). Three most important influential factors for treatment decision were doctor's recommendation, information from internet and spouse's advice. Most patients (88%) consulted more than 2 doctors while making a decision. Men with higher education (p=0.003) and higher income (p=0.003) tend to consult more doctors. Most respondents said that their doctor endorsed only one treatment, primarily surgery. 76% of the respondents said that their doctors recommended against watchful waiting. Men who underwent surgery considered doctor's recommendation as the most influential factor while those who had radiation considered information from internet, books and medical journals as most influential (p=0.018). Treatment choice was not influenced by PSA value at diagnosis. Subjects with higher education and higher income considered sexual function as a more influential factor while making a treatment choice. Better educated men preferred” informed decision making” over “complete reliance on doctor” (p=0.013). Non-married men found the decision more difficult to make (p=0.032), were more worried (p=0.0005) and experienced more distress (p=0.011) while making treatment decisions. Feeling of regret after treatment was experienced more by respondents with lower education (p=0.007) and lower income (p&amp;lt;0.0001). Conclusions: Patients younger than 50 years diagnosed with localized prostate cancer sought information from a wide range of sources but are influenced most by the doctor's recommendation. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-435.
Does U.S. Lag Behind Europe in Organ-Conserving Cancer Treatment?
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Does U.S. Lag Behind Europe in Organ-Conserving Cancer Treatment? Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 23, 6 December 1995, Pages 1736–1737, https://doi.org/10.1093/jnci/87.23.1736 Published: 06 December 1995
SAT0159 Podocyte damage by autoantibodies in lupus nephritis
Authors: A. Hillmann, E. Jung, H. Wardemann, T. Pap, A. Jacobi
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune disease, resulting in inflammation and tissue damage in several organs. This autoimmune reaction is caused by antibodies against dsDNA (adsDNAabs). Most patients with SLE develop joint pain and about 70% develop renal symptoms, partly with lupus nephritis leading to proteinuria. It is still unclear why the kidney and especially the podocytes (filtrating cells of the renal glomerulus) are involved in such a dramatic manner during SLE. <h3>Methods</h3> Anti dsDNA antibodies were isolated from SLE-patients, cloned and produced recombinantly in HEK293 cells. Podocytes were treated with equal amounts of different adsDNAabs and control antibodies in time and concentration dependent experiments and examined by immunofluorescence. To investigate the degradation mechanism, cells were treated with Bafilomycine A or MG132 at different time points of co-cultivation with the antibodies. <h3>Results</h3> adsDNA-antibodies are taken up by cultivated podocytes selectively. They turn up in cytosolic aggregates. The uptake of adsDNAabs occurs in a concentration and time dependent manner. We found podocytes with up to 80 aggregates per cell. In a recovery experiment, we could show that these aggregates are eliminated over time in media without adsDNAabs. The degradation of these adsDNAabs is reduced in experiments under autophagy inhibiting conditions (treatment with Bafilomycin A) and number of aggregates after the inhibition of autophagy rises significantly up to twofold. Stimulation of Autophagy by MG132 leads to a better survival of the cells. The number of aggregates of podocytes treated with a control antibody is almost zero. <h3>Conclusions</h3> Podocytes are postmitotic and highly complex cells. Loss of these cells leads to kidney injury and proteinuria. During lupus-nephritis, podocytes are destroyed. We could show that these cells take up SLE-antibodies selectively and are harmed by these antibody-aggregates. Furthermore, we have first evidence that the induction of autophagy can help to eliminate the aggregates. This should be considered for future therapeutic approaches in lupus nephritis. <h3>Disclosure of Interest</h3> None Declared
DRUG RELEASE PROFILE OF A NOVEL SIROLIMUS ELUTING BIORESORBABLE SCAFFOLD: IMPLICATION ON NEOINTIMAL FORMATION AND HEALING
Authors: Masahiko Shibuya, Kamal Ramzipoor, Chang Lee, Jennifer McGregor, Yanping Cheng, Serge Rousselle, Alex Estrada, Greg Kaluza, Juan Granada
Journal: Journal of the American College of Cardiology (2015)
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes
Authors: E Solary, L Mannone, D Moreau, D Caillot, R-O Casasnovas, H Guy, M Grandjean, J-E Wolf, F André, P Fenaux, P Canal, B Chauffert, A Wotawa, M Bayssas, P Genne
Journal: Leukemia (2000)
Dietary Supplementation with Olive Oil or Fish Oil and Vascular Effects of Concentrated Ambient Particulate Matter Exposure in Human Volunteers
Authors: Haiyan Tong, Ana G. Rappold, Melissa Caughey, Alan L. Hinderliter, Maryann Bassett, Tracey Montilla, Martin W. Case, Jon Berntsen, Philip A. Bromberg, Wayne E. Cascio, David Diaz-Sanchez, Robert B. Devlin, James M. Samet
Journal: Environmental Health Perspectives (2015)

Exposure to ambient particulate matter (PM) induces endothelial dysfunction, a risk factor for cardiovascular disease. Olive oil (OO) and fish oil (FO) supplements have beneficial effects on endothelial function.
OP0070 Anti-TNF Therapy and Tuberculosis Risk in Rheumatic Diseases, Psoriasis, and IBD: A Pooled-Data Analysis of Randomized Controlled Trials
Authors: V. Bruzzese, R. Lorenzetti, A. Zullo, C. Hassan, S. M. Campo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Treatment with tumor necrosis factor (TNF) antagonists has been recognized as a risk factor for active tuberculosis (TB), particularly for reactivation of latent infection. <h3>Objectives</h3> To evaluate the risk of TB in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PA), psoriasis (P), and inflammatory bowel diseases (IBD), treated with anti-TNF in randomized clinical trials (RCTs). <h3>Methods</h3> MEDLINE and Cochrane databases were searched to 31 March 2012 for RCTs evaluating Infliximab (IFX), Adalimumab (ADA), and Certolizumab (CER), the only three anti-TNF drugs used both for IBD and RA, AS, PA and P. Results were calculated by using fixed effects model and reported as pooled odd ratios. <h3>Results</h3> Overall, 86 RCTs with a total of 22,071 patients were considered, including 26 RCTs with 6,352 IBD patients, 45 RCTs with 11,638 rheumatic diseases (RA, AS, PA) patients, and 15 RCTs with 4,081 psoriatic patients. A total of 34 cases of TB were reported in patients (n= 14,478) who received anti-TNF therapy and none in controls (n = 7,593) (p&lt; 0.001). Of these, 29 cases were reported in patients with rheumatic diseases (p&lt; 0.001), 5 in IBD patients (p = 0.023), and none in psoriatic patients. Eight TB cases occurred by using a single anti-TNF drug (8,808 patients; OR: 9.9, CI 0.5-172.4), and 26 in RCTs by using an anti-TNF and Methotrexate combination (5,644 patients; OR: 48.3, CI 2.9-793.7). No difference emerged among IFX, ADA, and CER for TB risk. <h3>Conclusions</h3> Anti-TNF treatment significantly increases risk of TB infection. The risk seems to be particularly elevated in patients treated for rheumatic disease when a combination therapy with Methotrexate is used. <h3>Disclosure of Interest</h3> None Declared
P682Preserved contractile function of unloaded cardiomyocytes despite diminished sarcomere size is associated with troponin I activation
Authors: H Most, A Segiser, X Fu, C Zuppinger, ND Ullrich, SL Longnus, TP Carrel, HT Tevaearai
Journal: Cardiovascular Research (2014)

Objective: Myocardial unloading with ventricular assist devices in patients with severe heart failure (HF) can lead to reversal of certain aspects of pathological remodeling. However, these effects do not translate into recovery of myocardial function in the human heart, possibly due to detrimental atrophic processes also elicited through unloading. We have studied the effects of long-term unloading on sarcomeric morphology and function in a small animal model of ventricular unloading, heterotopic heart transplantation (HTX) in rats. Methods: Native rat hearts were unloaded via HTX for 30 days, CMs from control and unloaded hearts were isolated (n=8 hearts/>250 individual cells/group). CM overall size was determined, sarcomere length/contractility assessed and Calcium transients as well as E-C coupling gain analyzed in patch-clamped CMs. Additionally, phosphorylation of Troponin I, indicative of sarcomere activation, was measured with western blotting. Results: CM cross-sectional area was diminished in unloaded cells by about one third (2787±345 vs 1993±230 μm2) as was cell capacitance in patched cells. Accordingly, baseline sarcomere length was significantly reduced by ~0.2μm (Figure). However, this reduction did not diminish contractile function: fractional shortening was significantly higher in unloaded CMs (8.0 ± 3 % vs 6.6 ± 2.5 % in CTR, p = 0.01). Departure velocity of the transients was similar (-135.2 ± 48 vs -119.4 ± 40 dL/dt), and return velocity was slightly increased in unloaded cells (120.7 ± 54 vs 94.0 ± 46 dL/dt, p < 0.05), indicating preserved relaxation. Calcium transient amplitudes and current-voltage relationship under basal condition and isoproterenol stimulation was not changed. Troponin I phosphorylation was elevated and may contribute to the maintenance of sarcomeric function in long-term unloaded CMs. Conclusion: Although there are limitations regarding assessment of contractility in isolated cells, we may conclude that the considerable size reduction in CMs induced by unloading does not translate into diminished contractile function or E-C coupling.
GAMMA-GLUTAMYLTRANSFERASE STIMULATES TISSUE FACTOR EXPRESSION INDEPENDENT OF ITS ENZYMATIC ACTIVITY IN HUMAN MONONUCLEAR CELLS
Authors: Valentina Scalise, Cristina Balia, Silvana Cianchetti, Maria Franzini, Vittoria Carnicelli, Silvia Petrini, Tommaso Neri, Riccardo Zucchi, Alessandro Celi, Alessandro Corti, Roberto Pedrinelli
Journal: Journal of the American College of Cardiology (2015)